Scholar Rock (SRRK)
| Bid | 26.69 |
| Market Cap | 2.92B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -246.29M |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -12.45 |
| Forward PE | -25.41 |
| Analyst | Buy |
| Ask | 32.45 |
| Volume | 759,844 |
| Avg. Volume (20D) | 1,129,493 |
| Open | 29.54 |
| Previous Close | 29.76 |
| Day's Range | 29.48 - 30.77 |
| 52-Week Range | 6.76 - 46.98 |
| Beta | 0.58 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria...
Analyst Forecast
According to 6 analyst ratings, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $43.5, which is an increase of 41.46% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call TranscriptScholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco -...
2 months ago · seekingalpha.com
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment DataScholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 pr...
